Abstract 9P
Background
Despite the development of immune checkpoint inhibitors therapy (ICI) in non-small cell lung cancer (NSCLC) patients, most of them eventually experience relapse. Small extracellular vesicles (sEV) are currently emerging as promising biomarkers. They are released by all cell types and can be found in all body fluids. sEV reflect the state of the tumor at distance. Here, we investigated the immunosuppressive role of sEV derived from patient’s NSCLC (NSCLC-sEV) on anti-tumoral CD8+ T cells.
Methods
NSCLC-sEV were purified from NSCLC patient-derived cell lines or from tumor resection. Their immunosuppressive effects were studied by exposing healthy or tumor-infiltrated CD8+ T cells to NSCLC-sEV, where their activation, proliferation and viability were assessed. By NGS, the microRNA cargo of NSCLC-sEV were investigated. Using bioinformatic analysis, we identified potential immunosuppressive microRNAs included into NSCLC-sEV that were tested by direct transfection in CD8+ T cells.
Results
CD8+ T cells exposed to NSCLC-sEV showed reduced expression of their activation markers CD25 and CD45, and decreased secretion of anti-tumoral TNF alpha, granzyme B, and perforin-1, suggesting that they are unable to conduct an efficient anti-tumoral response. NSCLC-sEV also upregulated the CD8+ immune checkpoint markers, such as PD-1, TIGIT, and TIM-3, and decreased the viability and proliferation of exposed CD8+ T cells. Transfection of our candidate miRNAs, miR-29c-3p and miR-181b-5p, into CD8+ T cells induced an inhibition similar to that induced by native NSCLC-sEV.
Conclusions
NSCLC-sEV can impair CD8+ T cell response against the tumor by reducing their activation, proliferation, viability and by increasing the expression of immune checkpoints on their membrane. We demonstrated that these effects could be supported by their immunosuppressive miRNA cargo. Overall, our results describe the immunosuppressive functions of NSCLC-sEV.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
D. Fradin.
Funding
Ligue contre le cancer comité 22, 41, 44; Fondation ARC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1792P - Molecular characterization from IMfirst: Atezolizumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) in Spain
Presenter: Manuel Cobo Dols
Session: Poster session 07
1793P - Treatment and outcomes of limited disease small cell lung cancer (LD-SCLC) in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1794P - Deciphering ERBB2-driven mechanisms that regulate tumor immune evasion and metastasis in SCLC
Presenter: Lydia Meder
Session: Poster session 07
1795P - Consolidation serplulimab following concurrent hypofractionated chemoradiotherapy for limited-stage SCLC: Preliminary analysis of phase II ASTRUM-LC01 study
Presenter: Yuqi Wu
Session: Poster session 07
1796P - Smoking-related genomic mutation patterns in patients with small cell lung cancer treated in ASTRUM-005 study
Presenter: Ying Cheng
Session: Poster session 07
1798P - Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE)
Presenter: Sara Moore
Session: Poster session 07
1799P - Efficacy and safety of integrating consolidative thoracic radiotherapy with immunochemotherapy in ES-SCLC: A real-world retrospective analysis
Presenter: Qi Zhang
Session: Poster session 07
1800P - Breaking chemo-immunotherapy resistance in SCLC-patient derived tumor with novel DDRi combinations
Presenter: Carminia Della Corte
Session: Poster session 07
1801P - Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide
Presenter: Kenneth O'Byrne
Session: Poster session 07